Epstein-Barr Virus (EBV)-Specific T Cells as Therapy for Relapsed/Refractory EBV-positive Lymphomas

Inclusion Criteria: * Informed consent. * EBV-positive lymphoma as determined by in situ hybridization or equivalent (excluding Burkitts Lymphoma). * Age 18 years or older. * ECOG performance status 1, 2 or 3 * Life expectancy of at least 6 months. * Measurable disease: either relapsing, partially responsive, refractory or progressive disease, includes disease detected either by clinical examination, radiographic evaluation (including CT scans, and at physician's discretion by functional imaging), or a persistently detectable plasma EBV viral load. * No chemotherapy / radiotherapy and/or antibody therapy for at least 2 weeks prior to anticipated date of first infusion. Exclusion Criteria: * EBV negative tumour * Presence of detectable malignant cells in the peripheral circulation by flow cytometry or morphology * Serious infection within the past 28 days that has not adequately responded to therapy * Pregnancy, or unwilling to use adequate contraception * Serology (taken within 3 months of CTL release date) indicating active HBV or HCV infection, positive serology for HIV I\&II, HTLV1 or syphilis * Negative serology for EBV * Psychiatric, addictive or any condition which may compromise the ability to participate in this trial